Menu
Recruiting NCT06839209

Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea

No phase Interventional Clostridium; Difficile, As Cause of Disease Classified Elsewhere Clostridium Difficile Diarrhea

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Toxclean 1g.
Who it may be relevant to
Registry conditions: Clostridium; Difficile, As Cause of Disease Classified Elsewhere, Clostridium Difficile Diarrhea. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Pilot Study to Evaluate Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea

Overview

This is a single center, randomized, exploratory clinical investigation that will evaluate the safety and efficacy of Toxclean (ABResearch srl) as add on treatment to Standard therapy in 24 patients with recurrent CDAD. Eligible subjects will be adult patients with recurrent CDAD. Recurrent CDAD, for the purpose of this protocol, is defined as one or more new episode of diarrhea (Ned) within two months from the end of the SoC treatment. The objective of this pilot study is to evaluate whether 1 or 2 grams of Toxclean powder is orally administrable and well tolerated as add on treatment to SoC in patients with recurrent CDAD.

Detailed description

This is a single center, randomized, exploratory clinical investigation that will evaluate the safety and efficacy of Toxclean (ABResearch srl) as add on treatment to Standard therapy in 24 patients with recurrent CDAD.

Eligible subjects will be adult patients with recurrent CDAD. Recurrent CDAD, for the purpose of this protocol, is defined as one or more new episode of diarrhea (Ned) within two months from the end of the SoC treatment. The objective of this pilot study is to evaluate whether 1 or 2 grams of Toxclean powder is orally administrable and well tolerated as add on treatment to SoC in patients with recurrent CDAD. Primary

* Percentage of patients that complete Toxclean schedule treatment; Secondary * Safety and tolerability of two different dosage of oral Toxclean treatment; * Reduction of toxin amount in fecal sample; * Clinical response after 28-day oral administration of two different dosage of TOXCLEAN in combination with SoC therapy; * CDAD symptoms improvements during treatment and follow up periods; * Fecal concentration of Toxclean;

Interventions

  • Device Toxclean 1g
    1 g of Toxclean once or twice daily for 28 days

Primary outcome measures

  • Percentage of patients that complete Toxclean schedule treatment [Time frame: 28 days]
Secondary outcome measures (4)
  • the assessment of the safety and tolerability of two different dosage of oral Toxclean treatment [Time frame: 28 days]
  • the clinical response after 14-day oral administration of two different dosage of TOXCLEAN in combination with SoC therapy; [Time frame: 14 days]
  • the CDAD symptoms improvements during treatment and follow up periods [Time frame: 2 months]
  • Measurement of Toxclean fecal concentration of Toxclean [Time frame: 28 days]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years, male or female, at the time of informed consent
  • Signed informed consent by patient, or where applicable, patient's legally authorized representative;
  • Diagnosis of recurrent CDAD, defined as those episodes of C. Difficile associated diarrhea occurring 2-8 weeks after either the symptoms resolution of a previous CDAD episode or C. difficile negativization of fecal sample.
  • Detection of C. difficile toxins by nucleic acid amplification tests (NAAT), EIA or GDH;
  • Received at least one course of adequate antibiotic therapy for CDAD (≥ 10 days of vancomycin at a dose of ≥125 mg four times per day, ≥ 10 days of metronidazole at a dose of 500mg three times per day or fidaxomixin 200mg twice a day for 10 days)

Exclusion criteria

  • History of C. difficile complicating inflammatory bowel disease (Crohn's disease, ulcerative colitis), or history of bowel resection surgery (other than uncomplicated appendectomy) or history of other infectious diarrhea or diarrhea of unknown etiology since the initial episode of CDAD;
  • Participants who require oral anticoagulant medications, including but not limited to warfarin and NOACs (novel oral anticoagulants);
  • Major gastrointestinal surgery within 3 months of enrollment;
  • History of swallowing difficulties, including dysphagia or odynophagia for liquids or solids;
  • Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
  • Consumption of the following prescription medications during the current enrollment episode: Bezlotuxamab/Zinplava Is pregnant or lactating Known hypersensitivity to the active principle or excipients

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Supportive care

Study locations

Italy · 1 center
  • Policlinico Gemelli — Roma

Identifiers

NCT: NCT06839209 · TOXCCAD

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗